1. Market Research
  2. > Healthcare
  3. > Health Services Market Trends
NPS+ Multiple Sclerosis (US) 2016

NPS+ Multiple Sclerosis (US) 2016

  • December 2016
  • ID: 4833577
  • Format: PDF
  • By Firstword Pharma


Table of Contents


One brand comes out ahead as low satisfaction scores plague MS therapies. Is your brand far behind?

Multiple Sclerosis (MS) therapies have a big perception problem. Over a third of the doctors we surveyed are unhappy with available brands, and only one of the ten brands we looked at managed to eke out a positive satisfaction score. The rest are trailing far behind, even though doctors seem to have few concerns about efficacy.

Find out what they are concerned about, and what you can do to win them over, in FirstView’s NPS+ Multiple Sclerosis 2016 (US).
Based on a survey of 100 US-based neurologists, the report builds on the respected net promoter score (NPS) to compare loyalty for 10 major MS drugs, highlighting ways you can improve brand health—and boost market share—with easy-to-use KPIs.

Top Takeaways
- Unhappy market: Nearly half of doctors surveyed are unsatisfied with available therapies. One brand did manage a positive NPS, but just barely. Several others are deep in negative territory.
- Improving won’t be easy: Few respondents are sitting on the fence. To improve their scores brands must win over Detractors, who view them negatively. The report’s brand message effectiveness data may point the way to the right approach.
- Most brands have the potential for big share gains: Winning over Detractors would allow several brands to at least double their market share. Two brands in particular could see gains of 300% or more.
- Doctors are not afraid to switch: Loyalty scores are low across the board, and even among satisfied doctors, few promote one brand exclusively.
- Efficacy is not the issue: A look at the report’s Brand DNA section shows that even brand Detractors have few efficacy concerns. Find out what they are worried about.
- Waiting for the next breakthrough? Brand DNA also shows several doctors are concerned that certain brands are outdated, suggesting that they may be eager to see new treatments come to market.

Insight into 10 Major Multiple Sclerosis Brands
- Aubagio (teriflunomide; Genzyme)
- Avonex (interferon beta-1a; Biogen)
- Betaseron (interferon beta-1b; Bayer)
- Copaxone (glatiramer acetate; Teva)
- Gilenya (fingolimod; Novartis)
- Lemtrada (alemtuzumab; Genzyme)
- Plegridy (peginterferon beta-1a; Biogen)
- Rebif (interferon beta-1a; EMD Serono)
- Tecfidera (dimethyl fumarate; Biogen)v
- Tysabri (natalizumab; Biogen)

A Report Based on Expert Knowledge
We surveyed 100 US-based neurologists chosen from the largest community of validated physicians in the world. The same community that pharma market researchers trust for reliable, fast intelligence.

We conducted the survey between November 1st and 4th, 2016.

Explore Important Brand Loyalty Issues

NPS+ Multiple Sclerosis 2016 (US) explores key issues affecting brand loyalty for drug manufacturers.

You’ll learn:
- How satisfied the Myeloma market is.
- How loyal doctors are to your brand.
- How many other brands your Promoters recommend.
- Which other brands your Promoters and Detractors recommend.
- How much market share your brand has among Promoters and Detractors.
- How much market share you stand to gain by converting Detractors into Promoters.
- Which messages Promoters, Passives and Detractors associate with your brand.
- Your brand DNA: what doctors really think of your brand—in their own words.

What is Net Promoter® Score?
NPS is a customer loyalty metric developed by (and a registered trademark of) Fred Reichheld, Bain & Company, and Satmetrix. It was introduced by Reichheld in his 2003 Harvard Business Review article One Number You Need to Grow.

How does NPS work?
NPS measures overall brand satisfaction and loyalty by asking one simple question:

"How likely are you to recommend this brand to a colleague?"

Responses - given on a scale of 0 (not at all likely) to 10 (extremely likely)—are used to classify respondents into 3 categories:
Detractors are those who answer 0 – 6.
Passives are those who answer 7 – 8.
Promoters are those who answer 9 - 10.

How is NPS calculated?

The percentage of detractors - the percentage of promoters = NPS.

For example, 25% Promoters, 55% Passives and 20% Detractors give you an NPS of +5.

NPS can range from -100 (everybody is a Detractor) to +100 (everybody is a Promoter). The higher the score the healthier the brand.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020

  • $ 2000
  • January 2020

"Recurrent Head And Neck Cancer Squamous Cell Carcinoma - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2020" report offers comprehensive insights on marketed and Phase III products ...

Bone Metastasis - Pipeline Review, H2 2019

Bone Metastasis - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Bone Metastasis - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Bone Metastasis - Pipeline Review, H2 2019, provides an overview of the Bone Metastasis ...

Anaplastic Oligoastrocytoma - Pipeline Review, H2 2019

Anaplastic Oligoastrocytoma - Pipeline Review, H2 2019

  • $ 2000
  • December 2019

Anaplastic Oligoastrocytoma - Pipeline Review, H2 2019SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Anaplastic Oligoastrocytoma - Pipeline Review, H2 2019, provides an overview ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on